Printer Friendly

Many lack eye exam at start of hydroxychloroquine therapy.

FROM ARTHRITIS CARE & RESEARCH

Only one-third of lupus patient on Medicaid had a baseline retinal exam before initiating treatment with hydroxychloroquine, in an analysis of a claims database, despite the recommendation in clinical guidelines.

The analysis of 12,755 patients with systemic lupus erythematosus (SLE) on Medicaid from 29 of the most populated U.S. states between 2001 and 2010 found that 32.5% received a baseline dilated eye exam 30 days before, and up to 1 year after, starting treatment with the anchor drug hydroxychloroquine (HCQ). This figure rose to 40% when Humphrey visual field tests and other "optional" eye exams were included, reported Tzu-Chieh Lin, PhD, of Brigham and Women's Hospital, Boston, and his colleagues.

HCQ is known to cause retinal damage in some patients, binding to and accumulating in the retinal pigment epithelium melanin. If undetected, patients may gradually lose central vision. There is particular risk for HCQ-induced retinal damage in patients on higher doses (5 mg/kg or greater of actual weight), HCQ exposure over 5 years, or renal, hepatic, or retinal disease, the research team explained.

Baseline retinal examinations for first-time HCQ users were first recommended by American Academy of Ophthalmology guidelines in 2002, and in 2009 the American College of Rheumatology developed guidelines specifically for SLE that also recommended a funduscopic exam within 1 year of starting HCQ.

The proportion of patients beginning treatment with HCQ who received a retinal exam only slightly increased from 31% in 2001 to 34.4% in 2009 (P value for linear trend over time = .12).

Women were significantly more likely to have a baseline retinal exam (odds ratio, 1.30; 95% confidence interval, 1.08-1.55), and certain sociodemographic factors predicted who received a baseline exam, likely reflecting problems with adherence and access to health care. For example, the likelihood of having a baseline exam proved significantly lower for blacks and American Indian/Alaska natives (OR, 0.85; 95% CI, 0.77-0.93; and OR, 0.69; 95% CI, 0.47-1.02) than for whites, whereas Asian Americans had greater odds than whites (OR, 1.30; 95% CI, 1.061.60).

These factors "have been associated with differences in both access to care and adherence in the SLE Medicaid population for indicated care, including infection prevention, adherence to indicated medications including HCQ, treatments for lupus nephritis, and choices in renal replacement therapies and use of erythropoietin-stimulating agents among SLE end-stage renal disease patients," the researchers wrote.

"While adherence to daily dosing, by the latest recommendations less than 5 mg/kg actual weight, is a more important factor determining renal toxicity risk, baseline examinations are necessary to avoid treating patients with preexisting retinal disease and to allow early detection of changes from baseline," the researchers noted.

The Rheumatology Research Foundation and the National Institutes of Health funded the work. No disclosures were made.

SOURCE: Lin T et al. Arthritis Care Res. 2018 Feb 6. doi: 10.1002/acr.23530.

BY NICOLA GARRETT

dermnews@frontlinemedcom.com

COPYRIGHT 2018 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:LUPUS
Author:Garrett, Nicola
Publication:Dermatology News
Date:Mar 1, 2018
Words:496
Previous Article:SCSs not the drugs to use for long-term eczema treatment.
Next Article:Predictors may help to spot risk for hydroxychloroquine nonadherence.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |